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Red Blood Cell Transfusion and Long-term Major Adverse Events in Patients
Undergoing Percutaneous Coronary Interventions, Results from A Large
Prospective Multicenter Registry – the STENT Group
Hiroki Ito1, Matthew Cantrell1, Marcy Nussbaum2, James Hermiller1, Zachary
Hodes1, Charles Simonton2
1St. Vincent Heart Center of Indiana, Indianapolis, IN; 2Carolinas Medical Center,
Charlotte, NC
Background: Independent association between red blood cell transfusion (RBCT) and
all cause death has been reported in patients undergoing percutaneous coronary
interventions (PCI).
Methods: We utilized a subset of the STENT study, who underwent PCI during May
2003 - June 2006. All cause death, myocardial infarction (MI), and target vessel
revascularization (TVR) were used as the study outcomes. A propensity score model
was created to predict receiving RBCT. A one to five ratio of propensity score matched
patients with and without RBCT was used to produce adjusted Cox proportional hazard
ratios (HR).
Results: Of the total population (N=19,893), 570 patients (2.9%) received RBCT and
156 (0.78%) complicated with TIMI major bleeding. The study outcomes at 9 months
included all cause death 704 patients (3.5%), MI 611 (3.1%), and TVR 1093 (5.6%).
The propensity score model consisted of 24 baseline variables including hemoglobin
levels and had excellent fit for predicting RBCT (c-statistic 0.85). Adjusted HR of 9-
month all-cause death, MI and TVR comparing patients with and without RBCT were
2.3 (95% confidence interval: 1.6-3.1), 2.2 (1.6-3.2) and 2.1 (1.5-3.0), respectively.
RBCT remained as a significant predictor when adjusted with propensity score + TIMI
major bleeding event for the all outcomes: adjusted HR 2.3 (1.7-3.3), 2.2 (1.5-3.4) and
1.9 (1.3-2.8), respectively.
Conclusion: We demonstrated the independent association between RBCT and 9-
month major adverse events in patients undergoing PCI. A randomized trial of RBCT
strategies may be warranted to guide clinical practice.
TCT-392
The Frequency and Etiology of Readmission in the 30 days After Percutaneous
Coronary Intervention
Gregory W Yost, Stefanie L Puher, Thomas D Scott, Kimberly A Skelding, Donald
Nardone, John McB Hodgson, Peter B Berger, James C Blankenship
Geisinger Medical Center, Danville, PA
Background: Readmissions after percutaneous coronary intervention (PCI) are costly
and associated with increased mortality. Identifying the frequency and causes may lead
to strategies to prevent readmission.
Methods: Patients undergoing PCI (elective, urgent, and emergent) at our center
between 1/1/2007 and 4/12/2010 were prospectively entered into the American College
of Cardiology National Cardiovascular Data Registry (n=4,523). Patients readmitted
within 30 days of the index procedure were identified using an administrative database
(n=222). Phone calls to all PCI patients at 1 year identified 48 additional patients
readmitted to a non-Geisinger hospital. Individual charts were reviewed independently
by 2 investigators, and disagreements regarding cause for readmission were resolved
by a 3rd investigator. Reasons for readmission were categorized as: PCI complication,
cardiac cause related to index admission, non-cardiac cause related to index admission,
and unrelated to index admission. Variables associated with readmission with p<0.1
were considered for inclusion in a multivariable logistic regression model predicting
30-day readmission.
Results: Of 4,523 cases included for analysis, 222 (4.9%) were readmitted within 30
days. Thirty (14%) were due to a PCI complication, 87 (39%) were non-PCI related
but cardiac related to index admission, 13 (6%) were non-cardiac but related to index
admission, and 92 (41%) were not related to the index admission. Female sex, advanced
age, peripheral arterial disease, prior valvular surgery, and PCI complications during
index procedure were associated with higher likelihood of 30-day readmission.
Conclusion: After PCI, readmission within 30 days due to PCI complications is rare
(0.6% of all PCI). Most predictors of readmission are not modifiable (sex, age, prior
valve surgery, or urgent status of procedure). PCI complications are modifiable risk
factors, but eliminating all of these would have a small affect on the overall readmission
rate. 30-day readmission should not be used as a lone metric of quality of PCI
performance.
TCT-393
Incidence, predictors and long-term clinical outcomes of coronary perforation
in the modern era
Samer Mansour, Alexis Matteau, Francois Gobeil, Andre Kokis, Louis-Mathieu
Stevens, Nicolas Noiseux
Centre hospitalier de l’Universite de Montreal, Montreal, Canada
Background: Coronary perforation is a rare but life-threatening complication of
percutaneous coronary intervention (PCI). We aim to evaluate the incidence, predictors,
management, and clinical outcomes of patients with procedure-related coronary
perforation in the modern era.
Methods: We performed a database analysis in a Canadian high-volume tertiary center.
Clinical and procedural records and angiographic studies were reviewed. In-hospital
and long-term clinical follow-up were obtained.
Results: Between June 2008 and March 2011, 6647 patients underwent PCI.Coronary
perforation was noted in 20 patient(0.3%).The perforation population was notable for
its advanced age (73 +/- 9 years), high incidence of female sex (55%) and presentation
in acute coronary syndrome (65%) (All, P < .001 compared with patients without
perforation). Most lesions were complex (60% type C) and located in the right coronary
artery (40%). The perforation occurred following stenting in 30% and mostly post-
stenting dilatation with a non-compliant balloon in 65% of patients. No
rotablation-related perforation was noted. Type III perforation was noted in the majority
of cases (60%). Following perforation, immediate successful treatment was obtained
with prolonged balloon inflation in one case and covered stent implantation in 19 cases.
More than one stent graft was needed in 25% and urgent coronary artery bypass graft
surgery (CABG) and surgical repair was required in 2 cases because of covered stent
failure. During the procedure 55% (n=11) had hemodynamic instability/required
cardiopulmonary resuscitation and one patient died. The in-hospital myocardial
infarction (MI) rate was 60% (n=12), stroke rate was 5% (n=1) and target lesion
revascularisation (TLR) rate was 5% (n=1). The mean length of hospital stay was (7
+/- 6 days). At clinical follow-up (n=19, median: 482, range: 29-1030 days) no MI or
stroke was noted, however one patient (5%) died from an unknown cause one month
after the procedure and 2 patients (10%) required TLR (one CABG and one re-PCI).
Conclusion: Despite more aggressive approach with PCI to treat coronary artery
disease in the recent years, coronary perforation remains a rare complication associated
with complex lesions. However, it still implies significant morbidity and mortality.
TCT-394
Early and Long Term Results After Five–Hours Discharge Percutaneous
Coronary Interventions
R. Stefan Kiesz1, Magda D Konkolewska1, Radoslaw J Szymanski2, Barbara K
Wiernek2, Szymon L Wiernek2, Pawel E Buszman2
1San Antonio Endovascular & Heart Institute, San Antonio, TX; 2American Heart of
Poland, Katowice, Poland
Background: Since the first coronary angioplasty performed by Dr Andreas Gruntzig
in 1977, we have been witnessing the tremendous improvement in interventional
cardiology. New devices, stents, medical therapy and techniques contribute to the
improvement of safety, despite the increasing complexity of performed interventions.
We believe that, by combining direct thrombin inhibitor (Bivalirudin) with Vascular
Closure Devices, these developments allow us to safely discharge selected group of
patients 5 hours after Percutaneous Coronary Interventions (PCI). The aim of this study
was to evaluate early and late results of patients discharged on the same day after PCI.
Methods: Between December 2007 and April 2011, a total of 233 PCIs were
performed in 133 elective patients (66.9% Male). The mean age of patients was 57
(±10), 31.7% of the population was represented by Hispanics, 39.5% suffered from
diabetes and mean BMI was 31.1 (±7.6). All procedures were done with exclusive
usage of Bivalirudin and Mynx™ Vascular Closure Device. Patients were discharged
on average 4(+/- 2.5) hours after the procedure and treated with statins, dual antiplatelet
therapy and aggressive diabetes management (goal HbA1C<7). In the 30 day
observation, the primary end point (MACCE) was: Death, Myocardial Infarction,
Stroke and Target Vessel Revascularization (TVR); the secondary end point included
bleeding and vascular complications (retroperitoneal bleeding, urgent hospitalization,
pseudoaneurysm, hematoma, ecchymosis).
Results: During the mean follow-up time of 13.3 months (±10.8), the primary end
point was reached in 18 cases (7.7%), including 2 deaths (0.8%) and 16 TVRs (6.9%).
MACCE occurred on average 15.5 months (±8.2 months) after the procedure.
Secondary end point was noted in 37 (15.9%) cases including 34 ecchymoses, 1
hematoma <5cm, 1 pseudoaneurysm and 1 overnight hospital transfer.
Conclusion: This study suggests that five hours discharge after uncomplicated, elective
PCI via the femoral artery, performed by experienced operator in selected group of
patients ensures low complication rates and is both: feasible and safe.
TCT-395
Study Modifications and Primary Endpoint Reinterpretations Prior to FDA
Approval of High-Risk Cardiovascular Devices
Sanket S. Dhruva1, Lucy H Liu2, Lisa A Bero1, Rita F Redberg1
1UCSF, San Francisco, CA; 2Johns Hopkins University School of Medicine,
Baltimore, MD
Background: Study modifications and primary endpoint reinterpretations introduce
bias and reduce the certainty of research findings. Premarket Approval (PMA) is the
most rigorous Food & Drug Administration (FDA) review process, for novel and high-
risk devices, including coronary and non-coronary stents. It is unknown to what extent
study modifications and primary endpoint reinterpretations are used in PMA
applications.
Methods: We examined the Summary of Safety and Effectiveness Data for all PMA
cardiovascular devices approved from 2000 through 2010 and recorded all study
modifications and primary endpoint reinterpretations and compared stents to all
cardiovascular devices.
Results: Of the 29 coronary and non-coronary stent PMAs approved between 2000-
2010 with a study with at least one primary endpoint, 2 (7%) had some form of study
modification or primary endpoint reinterpretation. In contrast, of the 67 total
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